The main directions and prospects in polycystic ovary syndrome treatment
The article is devoted to the actual gynecological problem of women of reproductive age-polycystic ovarian syndrome (PCOS) and the possibilities of its pharmacotherapy. Difficulties in choosing the treatment of the disease are the need to take into account all clinical manifestations, not limited to...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Siberian Branch Publishing House
2021-12-01
|
| Series: | Сибирский научный медицинский журнал |
| Subjects: | |
| Online Access: | https://sibmed.elpub.ru/jour/article/view/694 |
| _version_ | 1826575711340593152 |
|---|---|
| author | A. N. Useinova E. A. Egorova E. A. Yelisheva А. М. Beitullaev K. N. Koryanova |
| author_facet | A. N. Useinova E. A. Egorova E. A. Yelisheva А. М. Beitullaev K. N. Koryanova |
| author_sort | A. N. Useinova |
| collection | DOAJ |
| description | The article is devoted to the actual gynecological problem of women of reproductive age-polycystic ovarian syndrome (PCOS) and the possibilities of its pharmacotherapy. Difficulties in choosing the treatment of the disease are the need to take into account all clinical manifestations, not limited to menstrual disorders and infertility. PCOS is usually accompanied by hirsutism, obesity, decreased glucose tolerance, and other manifestations in various organ systems associated with metabolic disorders. These manifestations significantly reduce the quality of life of patients and also require pharmacological correction. Currently, the first line of drugs in the treatment of PCOS remains combined oral contraceptives, which have been used by women for decades, but, unfortunately, have multiple adverse reactions. The latter is the reason for the search for other methods of pharmacotherapy that are highly effective and safe. Metformin is one these glucose-lowering drugs, which shows effectiveness in the treatment of PCOS. Drugs from such groups as glucagon-like peptide-1 receptor agonists are at the research stage, and the development of treatment tactics using glucose-lowering drugs that have antagonism to glucagon is continuing. Expanding the choice of pharmacotherapy, thanks to the search for new, more effective and safe drugs and combining it with other treatment methods, makes it possible to control PCOS taking into account the individual characteristics of patients. |
| first_indexed | 2024-03-08T14:33:10Z |
| format | Article |
| id | doaj.art-9c78acbc82e84c6bbcb39e90610381d5 |
| institution | Directory Open Access Journal |
| issn | 2410-2512 2410-2520 |
| language | Russian |
| last_indexed | 2025-03-14T13:19:02Z |
| publishDate | 2021-12-01 |
| publisher | Russian Academy of Sciences, Siberian Branch Publishing House |
| record_format | Article |
| series | Сибирский научный медицинский журнал |
| spelling | doaj.art-9c78acbc82e84c6bbcb39e90610381d52025-02-28T13:43:57ZrusRussian Academy of Sciences, Siberian Branch Publishing HouseСибирский научный медицинский журнал2410-25122410-25202021-12-01416182910.18699/SSMJ20210602390The main directions and prospects in polycystic ovary syndrome treatmentA. N. Useinova0E. A. Egorova1E. A. Yelisheva2А. М. Beitullaev3K. N. Koryanova4Crimean Federal University n.a. V.I. VernadskyCrimean Federal University n.a. V.I. VernadskyCrimean Federal University n.a. V.I. VernadskyCrimean Federal University n.a. V.I. VernadskyРyatigorsk Medical Pharmaceutical Institute of Volgograd Medical State University of Minzdrav of RussiaThe article is devoted to the actual gynecological problem of women of reproductive age-polycystic ovarian syndrome (PCOS) and the possibilities of its pharmacotherapy. Difficulties in choosing the treatment of the disease are the need to take into account all clinical manifestations, not limited to menstrual disorders and infertility. PCOS is usually accompanied by hirsutism, obesity, decreased glucose tolerance, and other manifestations in various organ systems associated with metabolic disorders. These manifestations significantly reduce the quality of life of patients and also require pharmacological correction. Currently, the first line of drugs in the treatment of PCOS remains combined oral contraceptives, which have been used by women for decades, but, unfortunately, have multiple adverse reactions. The latter is the reason for the search for other methods of pharmacotherapy that are highly effective and safe. Metformin is one these glucose-lowering drugs, which shows effectiveness in the treatment of PCOS. Drugs from such groups as glucagon-like peptide-1 receptor agonists are at the research stage, and the development of treatment tactics using glucose-lowering drugs that have antagonism to glucagon is continuing. Expanding the choice of pharmacotherapy, thanks to the search for new, more effective and safe drugs and combining it with other treatment methods, makes it possible to control PCOS taking into account the individual characteristics of patients.https://sibmed.elpub.ru/jour/article/view/694polycystic ovarian syndromecombined oral contraceptivesmetforminglucagon-like peptide-1 receptor agonists |
| spellingShingle | A. N. Useinova E. A. Egorova E. A. Yelisheva А. М. Beitullaev K. N. Koryanova The main directions and prospects in polycystic ovary syndrome treatment Сибирский научный медицинский журнал polycystic ovarian syndrome combined oral contraceptives metformin glucagon-like peptide-1 receptor agonists |
| title | The main directions and prospects in polycystic ovary syndrome treatment |
| title_full | The main directions and prospects in polycystic ovary syndrome treatment |
| title_fullStr | The main directions and prospects in polycystic ovary syndrome treatment |
| title_full_unstemmed | The main directions and prospects in polycystic ovary syndrome treatment |
| title_short | The main directions and prospects in polycystic ovary syndrome treatment |
| title_sort | main directions and prospects in polycystic ovary syndrome treatment |
| topic | polycystic ovarian syndrome combined oral contraceptives metformin glucagon-like peptide-1 receptor agonists |
| url | https://sibmed.elpub.ru/jour/article/view/694 |
| work_keys_str_mv | AT anuseinova themaindirectionsandprospectsinpolycysticovarysyndrometreatment AT eaegorova themaindirectionsandprospectsinpolycysticovarysyndrometreatment AT eayelisheva themaindirectionsandprospectsinpolycysticovarysyndrometreatment AT ambeitullaev themaindirectionsandprospectsinpolycysticovarysyndrometreatment AT knkoryanova themaindirectionsandprospectsinpolycysticovarysyndrometreatment AT anuseinova maindirectionsandprospectsinpolycysticovarysyndrometreatment AT eaegorova maindirectionsandprospectsinpolycysticovarysyndrometreatment AT eayelisheva maindirectionsandprospectsinpolycysticovarysyndrometreatment AT ambeitullaev maindirectionsandprospectsinpolycysticovarysyndrometreatment AT knkoryanova maindirectionsandprospectsinpolycysticovarysyndrometreatment |